Literature DB >> 2204536

Proconvulsant effect of SKF 38393 mediated by nigral D1 receptors.

G al-Tajir1, M S Starr, B S Starr.   

Abstract

This study investigated the hypothesis that the proconvulsant action of systemically applied dopamine D1 receptor stimulants is mediated by D1 receptors in the substantia nigra. Rats were equipped with bilateral stainless steel guide cannulas under halothane anaesthesia, to allow drugs to be injected into both nigras of conscious, unrestrained animals 7-14 days later. Bilateral intranigral administration of saline, together with a subconvulsant dose of pilocarpine (200 mg/kg), produced no convulsions in 14 rats. By contrast, intranigral SKF 38393 (2.5 micrograms) and pilocarpine (200 mg/kg) caused 18/22 rats to convulse. This proconvulsant action of SKF 38393 was completely attenuated by pretreatment with SCH 23390 (0.25 mg/kg). SCH 23390 (1 microgram) delivered into both nigras reduced the number of rats convulsing in response to 600 mg/kg pilocarpine (7/15, one fatally) as compared to saline-injected controls (12/13, eight fatally). These results indicate that dopamine D1 receptors in the substantia nigra (pars reticulata) mediate a proconvulsant action of dopamine, which is opposite to the anticonvulsant effect of the amine at striatal D2 receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204536     DOI: 10.1016/0014-2999(90)90283-c

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Bimodal effects of dopamine D2 receptor agonists on zero Mg(2+)-induced epileptiform activity in the rat cingulate cortex slice.

Authors:  A M Alam; M S Starr
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

2.  Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.

Authors:  Su-Hyuk Chi; Hyun-Ghang Jeong; Suji Lee; So-Young Oh; Seung-Hyun Kim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.